Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer

Published:2022-08-28 Issue:1 Volume:196 Page:175-183
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Gupta Tanya,Purington Natasha,Liu Mina,Han Summer,Sledge George,Schapira Lidia,Kurian Allison W.^ORCID

Funder

Breast Cancer Research Foundation

Richard and Susan Smith Family Foundation

Suzanne Pride Bryan Fund for Breast Cancer Research

Jan Weimer Junior Faculty Chair in Breast Oncology

Regents of the University of California’s California Breast Cancer Research Program

BRCA Foundation and the Biostatistics Shared Resource (BSR) of the NIH-funded Stanford Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10549-022-06716-y.pdf

Reference30 articles.

1. Coates AS et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98. J Clin Oncol 25(5):486–492

2. Amir E et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103(17):1299–1309

3. Chen Z et al (2005) Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study. Arch Intern Med 165(5):552–558

4. Forbes JF et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9(1):45–53

5. Elisaf MS et al (2001) Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37(12):1510–1513

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gynecologic Care of Black Breast Cancer Survivors;Current Breast Cancer Reports;2024-02-19

2. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer;Breast Cancer Research and Treatment;2023-06-16

3. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer;2023-03-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3